Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Nitisinone Tablets vs Orfadin
NCT02750345Phase 1Completed
- Sponsor
- Cycle Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nitisinone in hereditary tyrosinemia type 1 (HT1) (6 arms), sponsored by Cycle Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration Versus Time Curve (0-120h). Started Mar 2016; status: completed.
02
Drugs
nitisinone
03
Conditions
hereditary tyrosinemia type 1 (HT1)
Beyond the preview
Go deeper on NCT02750345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750345.